2002 Clinical Milestones

Region

Product

Milestone

US

Europe

US

US

US / Europe

US

US

Global

US / Europe

Germany

• Alpha-1-Antitrypsin

• ALYX Red Blood Cell

• Protein C (Ceprotin)

• Influenza Vaccine

• INTERCEPT Plasma

• INTERCEPT Platelets

• NeisVac-C (Mening C)

• Next Generation IGIV

• rAHF-PFM

• TBE Vaccine

Initiate Phase I

Initiate Clinicals

Initiate Phase III

Initiate Phase I/II

Submission for Approval

Submission for Approval

Initiate Phase II/III

Initiate Phase III

Submission for Approval

Complete Phase II/III

Europe

Europe

US

• Chemoprotectant Drug

• Cytostatic Drugs (2)

• Mafosfamide

Start Phase III Trials

Start Phase I Trials

Start Phase II/III

W. Europe

US

Japan

• EPO Omega

• Nextran

• Physioneal PD Solution

Initiate Phase III Clinicals

60 – 90 Days Survival

Initiate Clinicals

Previous slide

Next slide

Back to first slide

View graphic version